Documents | Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma | Guidance | NICE

Documents

A list of downloadable documents created during development.

Background information

Renal cell carcinoma: review decision - December 2014 information
Appendix A: decision paper presented to the Institute's Guidance Executive ^{PDF 62.34 KB} 30 May 2012
Appendix A: decision paper presented to the Institute's Guidance Executive ^{PDF 62.34 KB} 30 May 2012
TA178 Renal cell carcinoma: review decision - May 2012 information
TA178 Renal cell carcinoma: review proposal - March 2012 information
Appendix A: provisional matrix of stakeholders ^{MSWord 61.5 KB} 09 March 2012
Appendix B: proposal paper presented to the Institute's guidance executive ^{PDF 178.71 KB} 09 March 2012
NICE issues guidance on the use of other treatment options for renal cancer ^{PDF 33.1 KB} 06 December 2013

Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: appeal

Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: appeal information
Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: notice of appeal hearing information
Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: appeal announcement information
Roche
Roche: appeals received ^{PDF 74.34 KB} 13 July 2009
Roche: initial scrutiny letter ^{PDF 24.41 KB} 13 July 2009
Roche: response to scrutiny letter ^{PDF 46.76 KB} 13 July 2009
Roche: final scrutiny letter ^{PDF 14.69 KB} 13 July 2009
Wyeth
Wyeth: appeals received ^{PDF 88.98 KB} 13 July 2009
Wyeth: initial scrutiny letter ^{PDF 25.11 KB} 13 July 2009
Wyeth: response to scrutiny letter ^{PDF 79.46 KB} 13 July 2009
Wyeth: final scrutiny letter ^{PDF 17.53 KB} 13 July 2009
Wyeth: clarification letter ^{PDF 59.88 KB} 13 July 2009
Wyeth: response to clarification letter ^{PDF 13.54 KB} 13 July 2009
James Whale Fund for Kidney Cancer
James Whale Fund for Kidney Cancer: appeals received ^{PDF 66.33 KB} 13 July 2009
James Whale Fund for Kidney Cancer: initial scrutiny letter ^{PDF 25.64 KB} 13 July 2009
James Whale Fund for Kidney Cancer: response to scrutiny letter ^{PDF 104.83 KB} 13 July 2009
James Whale Fund for Kidney Cancer: final scrutiny letter ^{PDF 16.36 KB} 13 July 2009
Rarer Cancers Forum and Macmillan Cancer Support
Rarer Cancers Forum and Macmillan Cancer Support: appeals received ^{PDF 45.58 KB} 13 July 2009
Rarer Cancers Forum and Macmillan Cancer Support: initial scrutiny letter ^{PDF 26.52 KB} 13 July 2009
Rarer Cancers Forum and Macmillan Cancer Support: response to scrutiny letter ^{PDF 17.12 KB} 13 July 2009
Rarer Cancers Forum and Macmillan Cancer Support: final scrutiny letter ^{PDF 18.21 KB} 13 July 2009
Renal cell carcinoma: appeal decision ^{PDF 72.36 KB} 12 October 2009

Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: final appraisal determination

Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: final appraisal determination information
Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: final appraisal determination ^{PDF 254.2 KB} 22 April 2009
Response to consultee, commentator and public comments on the first ACD and comments from website consultation ^{PDF 286.25 KB} 22 April 2009
Response to consultee, commentator and public comments on the second ACD and comments from website consultation ^{PDF 440.52 KB} 22 April 2009
Consultee and commentator comments on the ACD
Bayer ^{PDF 45.1 KB} 28 April 2009
Department of Health ^{PDF 7.81 KB} 28 April 2009
Macmillan and Rarer Cancers forum ^{PDF 54.17 KB} 28 April 2009
NHS Quality Improvement Scotland ^{PDF 9.85 KB} 28 April 2009
Roche ^{PDF 119.13 KB} 28 April 2009
Royal College of Nursing ^{PDF 18.83 KB} 28 April 2009
Wyeth ^{PDF 122.11 KB} 28 April 2009
Expert comments on the ACD
David Chao ^{PDF 11.36 KB} 28 April 2009
Bill Savage ^{PDF 28.39 KB} 28 April 2009

Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma: final appraisal determination

Response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD)

Response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD) ^{PDF 474.99 KB} 10 February 2009

Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: appraisal consultation 2

Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: appraisal consultation 2
Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: appraisal consultation document 2 information
Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: evaluation report
Consultee and commentator comments on the first ACD
Bayer ^{PDF 28.97 KB} 04 February 2009
British Uro-oncology Group (BUG) ^{PDF 70.35 KB} 04 February 2009
Cancer Research UK ^{PDF 39.24 KB} 04 February 2009
Kidney cancer UK/James Whale fund for kidney cancer ^{PDF 69.56 KB} 04 February 2009
Macmillan and Rarer Cancers Forum ^{PDF 41.94 KB} 04 February 2009
National Kidney Federation ^{PDF 26.46 KB} 04 February 2009
NHS Cambridgeshire ^{PDF 28.85 KB} 04 February 2009
NHS Quality Improvement Scotland ^{PDF 17.43 KB} 04 February 2009
Novartis ^{PDF 19.6 KB} 04 February 2009
Pfizer ^{PDF 331.17 KB} 04 February 2009
Royal College of Physicians ^{PDF 46.17 KB} 04 February 2009
Roche ^{PDF 47.57 KB} 04 February 2009
Welsh Assembly Government ^{PDF 53.53 KB} 04 February 2009
Wyeth ^{PDF 85.38 KB} 04 February 2009
Wyeth 2 ^{PDF 21.53 KB} 04 February 2009
External expert comments on the appraisal consultation document
Dr David Chao ^{PDF 23.55 KB} 04 February 2009
Patient expert ^{PDF 17.46 KB} 04 February 2009
Bill Savage ^{PDF 19.57 KB} 04 February 2009
Report to the Appraisal Committee summarising comments (received by letter and email) on the appraisal consultation document - prepared by the Patient and Public Involvement Programme (PPIP) and Enquiry Handling team, September 2008 ^{PDF 1013.89 KB} 04 February 2009
Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic and economic evaluation - addendum to the report submitted on 2 May 2008 - prepared by Peninsula Technology Assessment Group (PenTAG), University of Exeter ^{PDF 155.54 KB} 04 February 2009
Extra work on bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma - prepared by Decision Support Unit ^{PDF 133.14 KB} 04 February 2009
First appraisal consultation document ^{PDF 232.59 KB} 04 February 2009
Response from the Assessment Group to comments on the Assessment report ^{PDF 209.6 KB} 04 February 2009
Consultee and commentator comments on the extra work consultation
Bayer ^{PDF 50.03 KB} 04 February 2009
British Uro-oncology Group ^{PDF 92.63 KB} 04 February 2009
Novartis ^{PDF 7.68 KB} 04 February 2009
Pfizer ^{PDF 34.9 KB} 04 February 2009
Roche ^{PDF 185.46 KB} 04 February 2009
Royal College of Nursing ^{PDF 20.14 KB} 04 February 2009
Royal College of Physicians ^{PDF 39.3 KB} 04 February 2009
Wyeth ^{PDF 59.06 KB} 04 February 2009
Extra work done by the Assessment Group (PenTAG) and the Decision Support Unit (DSU) on new data received ^{PDF 711.42 KB} 04 February 2009
External expert comments received on the extra work consultation
Pat Hanlon ^{PDF 14.73 KB} 04 February 2009
Dr David Chao ^{PDF 17.05 KB} 04 February 2009
Bill Savage ^{PDF 21.66 KB} 04 February 2009
Response from the DSU to comments on the extra work consultation ^{PDF 16.2 KB} 04 February 2009
Revised analyses submitted by Bayer incorporating the sorafenib patient access scheme and new price of sorafenib ^{PDF 361.69 KB} 04 February 2009
Extra work done by the DSU on the revised analyses submitted by Bayer ^{PDF 54.19 KB} 04 February 2009
Department of Health approval for the Technology Appraisal Committee to consider patient access schemes submitted for sorafenib and sunitinib
Department of Health approval of sunitinib patient access scheme ^{PDF 25.35 KB} 04 February 2009
Department of Health approval of patient access scheme for sorafenib ^{PDF 23.64 KB} 04 February 2009
Consultee and commentator comments on the executable economic model
Pfizer ^{PDF 9.21 KB} 04 February 2009
Bayer ^{PDF 16.98 KB} 04 February 2009
DSU addendum to the review of Roche's request for parameter changes ^{PDF 17.1 KB} 04 February 2009
Addendum to the pre-meeting briefing: end of life - a quantitative exploration ^{PDF 15.68 KB} 04 February 2009

Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: letter to consultees and commentators

Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: letter to consultees and commentators ^{PDF 39.39 KB} 31 October 2008

Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: appraisal consultation

Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: appraisal consultation
Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: appraisal consultation document information
Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: evaluation report
Renal cell carcinoma - sunitinib: assessment report ^{PDF 1.82 MB} 12 October 2009
Overview ^{PDF 352.75 KB} 07 August 2008
Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: consultee and commentator comments on the assessment report
Bayer ^{PDF 12.94 KB} 07 August 2008
Kidney Research UK ^{PDF 27.45 KB} 07 August 2008
NHS Quality Improvement Scotland ^{PDF 17.41 KB} 07 August 2008
Pfizer ^{PDF 46.16 KB} 07 August 2008
Pfizer 1 ^{PDF 128.35 KB} 07 August 2008
Pfizer 2 ^{PDF 418.47 KB} 07 August 2008
Roche ^{PDF 109.71 KB} 07 August 2008
Royal College of Nursing ^{PDF 20.98 KB} 07 August 2008
Royal College of Physicians ^{PDF 47.7 KB} 07 August 2008
Wyeth ^{PDF 182.88 KB} 07 August 2008
Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: non-manufacturer submission
Cancer Backup ^{PDF 50.34 KB} 07 August 2008
National Kidney Federation ^{PDF 98.67 KB} 07 August 2008
Joint submission from Kidney Cancer UK and James Whale Fund for Kidney Cancer ^{PDF 47.81 KB} 07 August 2008
Joint submission from NCRI Renal Clinical Studies Group/Royal College of Radiologists/Royal College of Physicians/Joint Collegiate Council for Oncology/Association of Cancer Physicians ^{PDF 68.99 KB} 07 August 2008
Kidney Research UK ^{PDF 26.83 KB} 07 August 2008
Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: manufacturer submissions (executive summary only)
Bayer ^{PDF 37.75 KB} 07 August 2008
Pfizer ^{PDF 83.02 KB} 07 August 2008
Pfizer - addendum to submission ^{PDF 52.04 KB} 07 August 2008
Roche ^{PDF 32.37 KB} 07 August 2008
Wyeth ^{PDF 73.87 KB} 07 August 2008
Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: expert written personal statements
Chao ^{PDF 21.63 KB} 07 August 2008
Hanlon ^{PDF 21.3 KB} 07 August 2008
Savage ^{PDF 38.43 KB} 07 August 2008
Patient Expert Statement ^{PDF 36.33 KB} 15 August 2008

Response to comments on pre referral remit and scope for STA sorafenib tosylate for advanced renal cell carcinoma

Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: final scope ^{PDF 34.72 KB} 03 October 2007

Response to comments on pre referral remit and scope for STA bevacizumab for metastatic renal cell carcinoma

Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: final scope ^{PDF 34.72 KB} 03 October 2007

Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: final matrix

Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: final matrix ^{PDF 48.35 KB} 03 October 2007

Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: final scope

Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: final scope ^{PDF 34.72 KB} 03 October 2007

Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: response to consultee and commentators comments on the scope

Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: final scope ^{PDF 34.72 KB} 03 October 2007

Renal cell carcinoma - bevacizumab, sarofenib and sunitinib: draft matrix

Renal cell carcinoma - bevacizumab, sarofenib and sunitinib: draft matrix ^{PDF 50.17 KB} 14 August 2007

Renal cell carcinoma - bevacizumab, sarofenib and sunitinib: draft scope

Renal cell carcinoma - bevacizumab, sarofenib and sunitinib: draft scope ^{PDF 36.9 KB} 14 August 2007

Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: final protocol

Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: final protocol ^{PDF 190.55 KB} 07 November 2007